Updated:
BioAsia Investments
BioAsia Investments is a family office headquartered in Palo Alto, investing in life sciences and healthcare across the US and Asia.
BioAsia Investments
BioAsia Investments is a family office headquartered in Palo Alto, California, with additional offices in San Diego, Redwood City, Carlsbad, San Francisco, Denver, Oslo, and Kowloon, suggesting a global sweep focused on life sciences and healthcare. The firm's exact founding year and founding principals are not publicly documented, and its wealth origin remains undisclosed. The firm invests across a range of life-science and healthcare sub-sectors, including biotechnology, digital health, medical devices, and healthcare services. Its geographic breadth — with US West Coast hubs, a Nordic outpost in Oslo, and a presence in Kowloon — points to a strategy that bridges American innovation with Asian market access. No specific portfolio companies, deals, or co-investors have been named publicly. BioAsia Investments does not disclose AUM, team size, or deployment figures. Its spread of office locations, however, indicates an operational footprint that is unusually broad for a family office of this scale. No recent operational events (within the last 24 months) have been identified in public sources. The firm's structural differentiator appears to be its multi-continent office network, which positions it to source and manage healthcare investments across North America, Europe, and Asia — a model that is relatively rare among single-family offices. However, without disclosed principals, track record, or deal history, its differentiation remains opaque.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Palo Alto
Corporate office
Palo Alto, CA, United States
Additional offices
San Diego · Redwood City · Carlsbad · San Francisco · Denver · Oslo · Kowloon
Sector focus
Frequently asked questions
Who runs investment decisions at BioAsia Investments?
No named principals or investment decision-makers have been publicly identified for BioAsia Investments. The firm's website, if it exists, is not indexed in major search engines, and its LinkedIn profile is not publicly available. Based on available public records, the leadership team remains unknown.
What investment stages does BioAsia Investments typically target?
The firm does not publicly disclose its stage preferences. Given its focus on life sciences and healthcare — sectors that often require long development timelines — it may engage across venture, growth, and later-stage opportunities. Without named portfolio companies or deal announcements, its stage focus cannot be confirmed.
Does BioAsia Investments participate in fund commitments or only direct deals?
No public information indicates whether the firm commits to external funds or solely pursues direct investments. Many healthcare-focused family offices use a hybrid model, but this has not been documented for BioAsia Investments.
Which sectors does BioAsia Investments explicitly avoid?
The firm does not disclose any explicitly avoided sectors. Its known office locations and broad healthcare scope suggest a focus on life sciences, but no exclusion list is publicly available.
Is BioAsia Investments structured as a single family office or does it operate more like a venture firm?
The firm is categorized as a single-family office, but its multi-city office network — spanning the US, Norway, and Hong Kong — is more extensive than what is typical for a single-family office. It may operate with a venture or investment firm posture, but this has not been confirmed in public sources.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: